Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Carboplatin affords superior QOL vs cisplatin in NSCLC

    • 7 Accesses

    This is a preview of subscription content, log in to check access.

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Carboplatin affords superior QOL vs cisplatin in NSCLC. Pharmacoecon. Outcomes News 446, 10 (2004). https://doi.org/10.2165/00151234-200404460-00025

    Download citation

    Keywords

    • Carboplatin
    • Mitomycin
    • Vinblastine
    • Tumour Response Rate
    • Entire Treatment Period